JP2024520730A5 - - Google Patents
Info
- Publication number
- JP2024520730A5 JP2024520730A5 JP2023574797A JP2023574797A JP2024520730A5 JP 2024520730 A5 JP2024520730 A5 JP 2024520730A5 JP 2023574797 A JP2023574797 A JP 2023574797A JP 2023574797 A JP2023574797 A JP 2023574797A JP 2024520730 A5 JP2024520730 A5 JP 2024520730A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cov
- domain
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163197952P | 2021-06-07 | 2021-06-07 | |
| US63/197,952 | 2021-06-07 | ||
| PCT/US2022/032201 WO2022260960A1 (en) | 2021-06-07 | 2022-06-03 | Virus-like particle vaccine for coronavirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520730A JP2024520730A (ja) | 2024-05-24 |
| JP2024520730A5 true JP2024520730A5 (https=) | 2025-06-10 |
Family
ID=84425412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574797A Pending JP2024520730A (ja) | 2021-06-07 | 2022-06-03 | コロナウイルスに対するウイルス様粒子ワクチン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240252621A1 (https=) |
| EP (1) | EP4351638A4 (https=) |
| JP (1) | JP2024520730A (https=) |
| KR (1) | KR20240019213A (https=) |
| CN (1) | CN118159288A (https=) |
| AU (1) | AU2022289462A1 (https=) |
| CA (1) | CA3221041A1 (https=) |
| IL (1) | IL308842A (https=) |
| MX (1) | MX2023014468A (https=) |
| WO (1) | WO2022260960A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4709741A1 (en) * | 2023-05-12 | 2026-03-18 | Icosavax, Inc. | Coronavirus spike glycoprotein receptor binding domains and uses thereof |
| CN121758566A (zh) * | 2023-11-03 | 2026-03-31 | 广东蓝玉生物科技有限公司 | 非洲猪瘟病毒e248r蛋白的免疫原性组合物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9585953B2 (en) * | 2011-03-22 | 2017-03-07 | Mucosis B.V. | Immunogenic compositions in particulate form and methods for producing the same |
| CN112521511B (zh) * | 2020-12-07 | 2023-03-14 | 中山大学 | 一种含EB病毒gB蛋白的自组装纳米颗粒及其制备方法与应用 |
-
2022
- 2022-06-03 MX MX2023014468A patent/MX2023014468A/es unknown
- 2022-06-03 IL IL308842A patent/IL308842A/en unknown
- 2022-06-03 EP EP22820815.3A patent/EP4351638A4/en active Pending
- 2022-06-03 KR KR1020247000038A patent/KR20240019213A/ko active Pending
- 2022-06-03 AU AU2022289462A patent/AU2022289462A1/en active Pending
- 2022-06-03 CA CA3221041A patent/CA3221041A1/en active Pending
- 2022-06-03 JP JP2023574797A patent/JP2024520730A/ja active Pending
- 2022-06-03 CN CN202280055149.2A patent/CN118159288A/zh active Pending
- 2022-06-03 US US18/565,728 patent/US20240252621A1/en active Pending
- 2022-06-03 WO PCT/US2022/032201 patent/WO2022260960A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9889194B2 (en) | Immunogenic composition for MERS coronavirus infection | |
| US5643577A (en) | Oral vaccine comprising antigen surface-associated with red blood cells | |
| JP4484904B2 (ja) | Ｄｎａ転写ユニットの接種による免疫化 | |
| JP2019526580A5 (https=) | ||
| US20110223198A1 (en) | dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants | |
| JP2021502350A5 (https=) | ||
| JP2024520730A5 (https=) | ||
| JP2003526676A (ja) | ワクチン用のアジュバント | |
| Cox et al. | Non‐lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication | |
| JP2024520730A (ja) | コロナウイルスに対するウイルス様粒子ワクチン | |
| US9913896B2 (en) | Attenuated parvovirus vaccine for muscovy duck parvovirus and goose parvovirus (derzsy's disease) | |
| US9889192B2 (en) | Immunization with rabies virus vector expressing foreign protein antigen | |
| JP2020536107A5 (https=) | ||
| JP2024510065A (ja) | 防御免疫の送達における、ｓａｒｓ－ｃｏｖ－２受容体結合ドメインに基づくワクチン組成物の使用 | |
| JP2024536600A5 (https=) | ||
| WO1998046263A1 (en) | Saponin adjuvants in combination with dna vaccination | |
| US5882649A (en) | Oral vaccine comprising antigen surface-associated with red blood cells | |
| RU2023134979A (ru) | Вакцина против коронавируса на основе вирусоподобных частиц | |
| Stephenson et al. | Rapid vaccination protocols for commercial vaccines against tick-borne encephalitis | |
| WO2007107597A2 (en) | Immunogenic construct and a method for the prophylactic or therapeutic treatment of aids | |
| Liu et al. | Use of novel DNA vectors and immunologic adjuvants in HIV vaccine development | |
| WO2025084106A1 (ja) | 経鼻投与による細胞性免疫の誘導方法 | |
| Albanesi et al. | Vaccination strategies and immunotherapy against influenza | |
| MXPA05003413A (es) | Uso del peptido gk-1 para potencial la respuesta inmunologica generada por la vacuna de influenza. | |
| WO2014176530A1 (en) | Vaccination methods |